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Antiretroviral Treatment for Pregnant Women Living with
HIV: A Summary of Issues, Interventions, and Evidence
Antiretroviral treatment (ART) for women living with HIV is vital to ensuring safe
motherhood and reducing vertical transmission. Each year, as many as 42,000 women
living with HIV die of HIV and pregnancy-related complications (Glass and Birx, 2016).
While significant progress has been made with 93% of pregnant women in 22 priority
countries who have accessed combination ART (or cART, formerly called HAART), not
all pregnant women can access treatment. In low- and middle-income countries in
particular, treatment access for pregnant women living with HIV has been hampered by
availability of medications and standardized treatment eligibility criteria that traditionally
prioritized prevention of HIV transmission to the infant over treatment for the health of
the woman.
Treatment Guidance Has Changed Dramatically
WHO’s September 2015 guidance states that
“ART should be initiated in all pregnant and
This section does not provide medical
breastfeeding women living with HIV at any
or clinical guidance, which is
CD4 cell count and continued lifelong,”
available from WHO, but rather a
(WHO, 2015f: 13), a treatment regimen also
public health perspective on what
known as Option B+. Global inequality may
works for women in access and
be reduced now that there is global agreement
adherence to ART in the context of
on when to start treatment. However, not all
antenatal care.
women will benefit immediately. The reality is
that, in 2015, fewer than one out of 10 people
living with HIV live in a country where ART upon HIV diagnosis is current policy or
practice (Health Gap, 2015).
Antiretroviral Medications are Beneficial, But Drug Resistance Remains a Concern for
Women Living with HIV
Concerns about taking cART during pregnancy are outweighed by the benefits. Studies
show that women living with HIV who access ART prior to pregnancy or very early in
pregnancy have no differences in rates of birth defects in fetuses/infants with first
trimester use of ART compared with ART initiation later in pregnancy (USHHS, 2015: c-

6). Since Option B+ calls for lifelong treatment, women living with HIV are at lesser risk
of developing drug resistance, unless they stop and start the recommended treatment, are
non-adherent, face drug stockouts, receive inappropriate regimens, etc.. Some women
may face worse outcomes on cART due to earlier WHO-recommended regimens during
previous pregnancies.
All Women Living with HIV Need Timely Access to ART, Ideally Prior to Pregnancy
Adolescent girls are especially important in antenatal care treatment programming
because of their increased vulnerability. Women who are part of key populations, such as
women who use drugs and women who are sex workers, also need intensified
programming to ensure ART access. “Motherhood is common among female sex
workers,” yet sex workers fear health services or avoid services, due to stigma and
discrimination (Papworth et al, 2015; S154).
Women’s Lives Are as Important as Their Children’s
Maternal HIV status and health is key to survival for infants and children in the postneonatal period. A recent study in Malawi found that the mother’s HIV-positive status
correlated with more than one-third of deaths of children up to age four. Children whose
mothers died were at greater risk of dying than those whose mothers were alive (Chihana
et al., 2015). Focus group discussions among women living with HIV in Malawi found
that Option B+ is presented to women as a program primarily to protect the baby, with
their health unimportant (Hsieh, 2013).
Few countries have comprehensive registers that follow the mother-infant pair after
delivery to measure longer-term cART adherence (UNAIDS, 2015). In order to
adequately assess if mothers are adhering well and are being kept alive, national
governments should continue to track:
• What % of pregnant women living with HIV access ANC and cART (Dourado et
al., 2014; Hlarlaithe et al., 2014);
• What % of pregnant women living with HIV are virally suppressed with cART;
• What % of women living with HIV who remain virally suppressed with cART by
number of years postpartum.
Women Need Information, Support and Respect in Decision-Making About
Antiretroviral Therapy
While WHO does not specify how quickly a
pregnant woman should initiate cART upon “I was really in favour of early
an HIV-positive diagnosis, countries that are treatment and to have this Option
implementing Option B+ are interpreting the B+. But now my worry is: are we
guidance to mean immediately. Yet initiating being given this as an option or is
treatment upon diagnosis may be too this being pushed on us with no
challenging for some pregnant women. option?” -Woman living with HIV in
Women in South Africa noted that they faced Zimbabwe (ATHENA et al., 2015: 3).
a triple burden of transitioning into
pregnancy, accepting a new HIV-positive serostatus and recognizing the need to start
lifelong ART as soon as possible (Stinson and Myer, 2012). Insufficient counseling or
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respect for women’s decision-making time can drive women away from accessing
treatment.
Fear of Disclosure, Violence Can Influence Treatment Initiation and Adherence
Pregnant women living with HIV still remain highly stigmatized in many countries.
While “disclosure of one’s HIV status can help to improve uptake and retention in
prevention of mother-to-child transmission of HIV services…” (Tam et al., 2015: 436),
some women are reluctant to disclose, particularly to their sexual partners (Croce-Galis et
al., 2015). As one woman living with HIV, diagnosed during pregnancy, put it: “…I
won’t tell him, because I need him, because he helps me with money. I can’t lose him
now because I can’t manage to have this baby if he doesn’t support me” (Sewnunam and
Modiba, 2015: 63). In some cases, disclosure may place a pregnant woman at risk. For
example, pregnant women in Zimbabwe have faced violence for testing without their
partner’s consent (Shamu et al., 2014).
Addressing Gender Norms and Supporting Women May be Key to Eliminating Vertical
Transmission
Women may face other gender related barriers to accessing health services (Croce-Galis
et al., 2015), as one woman noted in Cote d’Ivoire, who said that her husband would not
give her the funds to get transport to services (Schechter et al., 2014). A barrier to
initiation, adherence and retention on ART for pregnant women living with HIV is that
she may be required to ask permission to access services (Hodgson et al., 2014;
Hlarlaithe et al., 2014). Key to gender transformative programming in Safe Motherhood
and Prevention of Vertical Transmission is for women’s lives to be valued – not just to
keep babies healthy. Community-based support programs for pregnant women living
with HIV can be helpful. A recent study of implementation of community-based
adherence clubs for stable ART patients, which provided ART to 2,133 patients, 71%
female, with a strong emphasis on peer-based support and patient self management,
found that one year later, only 6% of patients were lost to follow up and fewer than 2% of
patients experienced viral load rebound (Grimsrud et al., 2015).
Additional Efforts are Needed to Better Engage Men in Supporting Safe Motherhood
and Prevention of Vertical Transmission
Little work has been done to explain vertical transmission to male partners and how men
can support pregnant partners living with HIV (Auvinen et al., 2014b). Interviews with
male partners of pregnant women living with HIV in South Africa found that men felt
responsible for their children, but that long clinic lines and the view that clinics for
maternal health care are women-only spaces reduced the likelihood that men will access
services through antenatal care (Koo et al., 2013a). Remarkably little is known about
couples and their relationships in the context of HIV and how to improve couple
communication around sensitive topics around risk, sex and transmission (RamirezFerrero and Lusti-Narasimhan, 2012). More nuanced efforts are needed to engage men in
prevention of vertical transmission.
It IS Possible to Eliminate Vertical Transmission
Between 2009 and 2015, there has been a 46% decline in the number of AIDS-related
deaths among women of reproductive age in the 21 priority countries (UNAIDS, 2016), a
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remarkable achievement. In June 2015, Cuba became the first country to be validated as
having met the global criteria for eliminating vertical transmission as a public health
problem, that is, in 2014, fewer than 50 new infections in 100,000 live births; a rate of
under 5% in breastfeeding women and less than 2% among women who do not breastfeed
(WHO, 2015a, cited in UNAIDS, 2015; Gulland, 2015).
***
The following interventions have been successful in improving treatment for pregnant
women living with HIV. See www.whatworksforwomen.org for more details, including
full citations, detailed methodology, and critical gaps in the literature.
What Works—Safe Motherhood and Prevention of Vertical Transmission: Antenatal
Care – Treatment
1. Initiating cART as early as possible to achieve low viral load is optimal, improves
maternal health, and reduces risk of vertical transmission. Supported by 19 studies in 30
countries
2. Peer counseling by mother mentors may improve treatment adherence among pregnant
women living with HIV. Supported by 6 studies in 8 countries
3. Community health workers and community-based support can increase uptake of safe
motherhood interventions for women living with HIV and reduce vertical transmission.
Supported by 9 studies in 7 countries
4. PMTCT-Plus (family-focused) HIV care can increase the numbers of women and their
partners who access treatment and remain adherent. Supported by 4 studies in 9 countries
5. Integrating ARV therapy into antenatal care, rather than referring women separately for
HIV treatment, can reduce time to treatment and increase adherence for pregnant women
living with HIV. Supported by 10 studies in 5 countries
6. National scale-up of cART in pregnancy improves maternal and infant outcomes.
Supported by 5 studies in 4 countries

What Works for Women and Girls is supported by the U.S. President’s Emergency Plan
for AIDS Relief (PEPFAR) and is carried out under the auspices of USAID’s Evidence
Project and What Works Association.
For more information please visit www.whatworksforwomen.org
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